Patrick Campbell

A look into how SGLT2 inhibitors, GLP-1 RAs, and nsMRAs have redefined the management of cardio-kidney-metabolic diseases.

Data from SURMOUNT-5, a head-to-head trial, demonstrate tirzepatide offered greater weight loss benefits than semaglutide.

Our Endocrinology Month in Review for November 2024 highlights recent headlines in diabetes and endocrinology as well as 5 new episodes of Diabetes Dialogue.

Our Cardiology Month in Review for November 2024 spotlights the approval of acoramidis and top content from AHA 2024.

With approval, acoramaidis becomes the first agent with a label specifying near-complete stabilization of TTR.

Ahmad Masri, MD, MS, discusses data from the FOREST-HCM trial examining effects of aficamten in patients with oHCM eligible for septal reduction therapy at baseline.

Ahmad Masri, MD, MS, discusses a study from AHA 2024 detailing changing risk profiles and outcomes in trials among patients with ATTR-CM.

Stephen Nicholls, MBBS, PhD, provides additional insight into KRAKEN trial data and the potential of muvalaplin.

Stephen J. Nicholls, MD, PhD discusses the robust efficacy and tolerability of zerlasiran for Lp(a) lowering, paving the way for Phase 3 development.

Muthiah Vaduganathan, MD, MPH, discusses the need for cardiology to embrace a role for GLP-1 receptor agonists and incretin therapies, with a focus on obesity-related HFpEF.

Viet Le, PA-C, DMSc, breaks down new data and updates from AHA 24, spotlighting 3 specific trials and the applicability of artificial intelligence in care.

Muvalaplin, an oral treatment, reduced Lp(a) by up to 85% in a 12-week Phase 2 trial presented at AHA 2024.

Zerlasiran reduced Lp(a) by over 90% at 60 weeks with consistent efficacy and no serious drug-related adverse events, supporting its phase 3 trial progression.

More than half of US adults—approximately 137 million—are candidates for semaglutide based on diabetes, weight management, or cardiovascular prevention indications.

Orly Vardeny, PharmD, MS, discusses the management and monitoring of hyperkalemia among patients with heart failure with preserved ejection fraction using finerenone.

Ankeet Bhatt, MD, MBA, ScM, provides additional insight into NUDGE-FLU data he presented at AHA 2024.

Electronic messages highlighting cardiovascular benefits of flu shots increased vaccination rates by 1.8% in heart attack survivors.

Oussama Wazni, MD, discusses the results of the OPTION trial examining LAAC in atrial fibrillation as well as its reception as AHA 2024.

Obesity-related ischemic heart disease deaths rose from 1999 to 2020, particularly in middle-aged men and Black adults, per CDC WONDER data.

Ankeet Bhatt, MD, MBA, discusses a study he led from AHA 2024 examining the cost-effectiveness of dapagliflozin based on how soon therapy was initiated following diagnosis or hospitalization.

Tirzepatide reduced the risk of heart failure hospitalization or cardiovascular death by 38% and improved body weight by up to 21% in the SUMMIT trial.

MJH Life Sciences, parent company of HCPLive, has acquired the RAD Annual Meeting, a premier CME-certified conference advancing dermatology knowledge and research.

Research presented at NASPGHAN 2024 found most children with chronic hepatitis C had neurodevelopmental disorders, highlighting the need for proactive care.

A Q&A with a pediatric gastroenterologist on new data detailing trends in water bead injuries in the US from 2013 through 2023.

PEDFIC data at NASPGHAN 2024 show mild, transient diarrhea events with odevixibat for cholestatic pruritus in PFIC, resolving in most cases.

A 10-year study reveals a surge in water bead injuries in young children, with an increase in cases requiring surgical intervention for bowel obstructions.

Meta-analysis of 30 studies highlights serum markers as prognostic tools for liver survival post-portoenterostomy in biliary atresia.

Linaclotide trial shows effective constipation relief for pediatric patients with neurodevelopmental disorders, with high treatment adherence and safety profile.

New data from the UNOS database presented at NASPGHAN 2024 details characteristics and outcomes of pediatric liver transplant patients receiving machine perfused organs.